Working... Menu

Coffee and In-vivo Oxidative Stress

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00868205
Recruitment Status : Completed
First Posted : March 24, 2009
Last Update Posted : February 28, 2012
Mondelēz International, Inc.
Information provided by (Responsible Party):
W.J. Pasman, TNO

Brief Summary:
Food and beverage intake that leads to a decrease in the level of in vivo markers of oxidative stress indicates that such foods and beverages act as antioxidants (AOX) in humans. Coffee drinking at a high level (> 900 ml/day) for a short period of time (1 week) has been shown to reduce DNA oxidative damage—as indicated by a decrease in the level of percent tail DNA (%T)— in study populations comprised mainly of young adults aged < 30 years. It is not clear whether such findings remain present over a longer period of time, and to extend such findings across a population that is more representative of European adults who consume common daily intakes of coffee, which is a low-to-moderate daily intake level (< 750 ml/day). As such, the investigators propose to determine the effect of drinking 3 and 5 cups of coffee per day (equivalent to 450 and 750 ml per day, respectively) for 8-weeks on markers of in vivo oxidative stress relative to control in a population of healthy adults free of chronic diseases aged 35 to 65 years. To ensure that overall health is considered, the investigators will also evaluate the effect on markers of cardiovascular health, inflammation, and glycemic control.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Coffee consumption Phase 2

Detailed Description:

Objective: The main objective of the present study is to determine the short- and mid-term effects of a coffee, on oxidative stress parameters in humans.

Study design: randomized, placebo-controlled, investigator-blinded, 3-arm parallel Study population: 168 apparently healthy volunteers: males and females aged >=35 and <= 65 years.

Intervention: The treatments consist of daily consumption of either:

Treatment 1: 0.45 L coffee (3 cups) and 0.30 L bottled water daily or; Treatment 2: 0.75 L coffee (5 cups) daily or; Treatment 3: 0.75 L water daily Duration of the treatment intervention is 8 weeks. Before the intervention period starts, a run-in period of five weeks where all subjects maintain their low antioxidant diet (Dutch average) is conducted by all subjects in order to standardize the antioxidant intake of the subjects.

Main study parameters/endpoints: Mean level of %T as a measure of DNA oxidative damage at week 8. Secondary outcome is the mean level of 8-isoprostane in 24 hr urine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Prevention
Official Title: The Relationship Between Short- and Mid-term Intake of Coffee on in Vivo Levels of Oxidative Stress Parameters in Healthy Adults.
Study Start Date : March 2009
Actual Primary Completion Date : July 2009
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: low coffee dose
3 cups of coffee daily for 8 weeks
Dietary Supplement: Coffee consumption
3 or 5 cups of coffee daily for eight weeks

Experimental: high coffee dose
5 cups of coffee daily for eight weeks
Dietary Supplement: Coffee consumption
3 or 5 cups of coffee daily for eight weeks

No Intervention: Control
Consumption of water instead of coffee daily for eight weeks

Primary Outcome Measures :
  1. DNA oxidative damage (Comet assay, %T) [ Time Frame: week 0, 4, 5,6,9 and 13 ]

Secondary Outcome Measures :
  1. Lipid oxidative damage (8-isoprostane in urine) [ Time Frame: week 5,6,9,13 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy as assessed by the

    • health and lifestyle questionnaire, (P8353 F02; in Dutch)
    • results of the pre-study laboratory tests
  2. Males and females aged >= 35 and <= 65 years at Week 01 of the study
  3. Body Mass Index (BMI) >= 20.0 but <= 34.9 kg/m2
  4. Blood pressure (automated measurement at site): systolic blood pressure <= 139 mm Hg and diastolic blood pressure <= 89 mm Hg
  5. Fasting glucose <= 6.9 mmol/L
  6. No smoking or moderate smoking of 1 to 19 cigarettes per day, with the proportion of smokers and nonsmokers representative of the European adult population aged 35-65 years
  7. Normal European eating habits as assessed by P8353 F02. Fruit and vegetable consumption at a level representative or less for the European population as assessed by P8353 F06
  8. Habitual caffeinated coffee drinker who consumes > 1 cup per day on at least 5 days per week as assessed by P8353 F02
  9. Voluntary participation
  10. Having given written informed consent
  11. Willing to comply with the study procedures
  12. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
  13. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

Exclusion Criteria:

Subjects with one or more of the following characteristics will be excluded from participation:

  1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
  2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
  3. Having a history of medical or surgical events that may significantly affect the study outcome (including cardiovascular disease or hypertension at repeated measurements, hypercholesterolemia, hyperglycaemia, kidney or liver disease, cancer, mental illness) based on the health questionnaire
  4. Hypertension as indicated by a systolic BP >= 140 mm Hg or a diastolic BP >= 90 mm Hg
  5. Hypercholesterolemia as indicated by a fasting LDL-cholesterol >= 4.9 mmol/L at a single screening visit or the use of anti-hypercholesterolemia drugs
  6. Diabetes as indicated by a fasting blood glucose >= 7.0 mmol/L at a single screening visit
  7. Having (a history of) (severe) gastro-intestinal complaints
  8. Using medication for high blood pressure, high cholesterol level, gastro-intestinal complaints, or antidepressants. With the exception of medication for heartburn
  9. Not willing to give up the use of coffee, tea, dark chocolate (and foods/beverages containing dark chocolate), vitamin supplements, mineral supplements, herbal products (food, beverage, or supplements), antioxidant dietary supplements, omega-3 fatty acid supplements including flaxseed oil and fish oil supplements, red wine or rose wines, port, sherry, or specific fortified foods
  10. Not willing to give up the consumption of coffee beans as food or in foods or the consumption of coffee or espresso in foods (e.g. Tiramisu)
  11. The use of any non-study caffeinated/decaffeinated coffee beverage or caffeinated/decaffeinated espresso-based beverage (espresso, cappuccino, latte, frappuccino, or frappe
  12. Alcohol consumption > 28 units/week for males and > 21 units/week for females
  13. Eating lots of fruit and vegetables (i.e. more than 400 gram vegetables per day and more than 4 servings of fruit per day at screening and during the study. This is twice that of the Dutch dietary recommendations for fruit and vegetable intake)
  14. Changing smoking habits (> 5 cigarettes per day)
  15. Exercising heavily (> 7 hours/week)
  16. Not willing to give up supplement (antioxidant containing) use (to be specified)
  17. Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
  18. Reported slimming or medically prescribed diet
  19. Reported vegan, vegetarian or macrobiotic
  20. Recent blood donation (<1 month prior to the start of the study)
  21. Not willing to give up blood donation during the study.
  22. Pregnant or lactating or wishing to become pregnant in the period of the study
  23. Personnel of TNO Quality of Life, their partner and their first and second degree relatives
  24. Not having a general practitioner
  25. Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00868205

Layout table for location information
TNO Quality of Life
Zeist, Utrecht, Netherlands, 3700 AJ
Sponsors and Collaborators
Mondelēz International, Inc.
Layout table for investigator information
Principal Investigator: Wilrike Pasman, PhD TNO

Additional Information:
Layout table for additonal information
Responsible Party: W.J. Pasman, TNO, Zeist, The Netherlands, TNO Identifier: NCT00868205     History of Changes
Other Study ID Numbers: P8353
First Posted: March 24, 2009    Key Record Dates
Last Update Posted: February 28, 2012
Last Verified: February 2012

Keywords provided by W.J. Pasman, TNO:
oxidative stress
Comet assay